1. Home
  2. FOXX vs AKTX Comparison

FOXX vs AKTX Comparison

Compare FOXX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foxx Development Holdings Inc. Common Stock

FOXX

Foxx Development Holdings Inc. Common Stock

HOLD

Current Price

$4.57

Market Cap

16.9M

Sector

N/A

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.48

Market Cap

17.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
AKTX
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
17.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FOXX
AKTX
Price
$4.57
$0.48
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
2.7M
464.5K
Earning Date
11-18-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,030,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
139.29
N/A
52 Week Low
$1.71
$0.42
52 Week High
$11.00
$1.73

Technical Indicators

Market Signals
Indicator
FOXX
AKTX
Relative Strength Index (RSI) 59.39 37.17
Support Level $1.71 $0.42
Resistance Level $6.90 $0.50
Average True Range (ATR) 0.89 0.06
MACD 0.28 0.00
Stochastic Oscillator 54.12 29.62

Price Performance

Historical Comparison
FOXX
AKTX

About FOXX Foxx Development Holdings Inc. Common Stock

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: